To The Moon
Home
News
TigerAI
Log In
Sign Up
Investcub
+Follow
Posts · 252
Posts · 252
Following · 0
Following · 0
Followers · 0
Followers · 0
Investcub
Investcub
·
2023-03-27
$Orbital Infrastructure Group, Inc.(OIG)$
看
1.80K
回复
Comment
点赞
4
编组 21备份 2
Share
Report
Investcub
Investcub
·
2022-12-07
$Alibaba(BABA)$
看
1.55K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Investcub
Investcub
·
2022-05-25
$Orbital Energy Group(OEG)$
😔
看
2.28K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
Investcub
Investcub
·
2022-05-25
$Alibaba(BABA)$
To the sky pls...
看
2.06K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Investcub
Investcub
·
2022-02-25
Bracing ... 🤕
U.S. Stocks Poised to Fall as Russia Continues Ukraine Onslaught
Stock futures decline, while Russian shares jump and oil prices edge higherU.S. stocks were poised f
U.S. Stocks Poised to Fall as Russia Continues Ukraine Onslaught
看
1.70K
回复
Comment
点赞
8
编组 21备份 2
Share
Report
Investcub
Investcub
·
2022-01-19
Tell me your opinion about this news...
3 Unstoppable Growth Stocks to Buy If There's a Stock Market Sell-Off
These three top growth names are already down a lot and trade at fair prices, but could become really huge bargains if the market falls more amid rising interest rates.
3 Unstoppable Growth Stocks to Buy If There's a Stock Market Sell-Off
看
1.80K
回复
Comment
点赞
6
编组 21备份 2
Share
Report
Investcub
Investcub
·
2022-01-19
Insightful !
Intel stock has a bright near-term future, says analyst
Despite lingering long-term challenges, Intel could deliver a positive earnings surprise, analyst sa
Intel stock has a bright near-term future, says analyst
看
2.41K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Investcub
Investcub
·
2022-01-08
Great to learn about Vir Biotech….
3 COVID Stocks That Will Make Billions in 2022
These three COVID-19 stocks could rake in a tremendous amount of cash this year.
3 COVID Stocks That Will Make Billions in 2022
看
2.33K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
Investcub
Investcub
·
2022-01-06
Another company added to watchlist!!!!
Alterity Therapeutics Soared Over 36% in Premarket Trading
Alterity Therapeutics soared over 36% in premarket trading.Alterity Therapeutics (ASX:ATH) secured a
Alterity Therapeutics Soared Over 36% in Premarket Trading
看
2.42K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
Investcub
Investcub
·
2021-12-30
Good to know
Two Doses of J&J’s Vaccine Slashes Omicron Hospital Stays
Booster shot following the one-dose vaccine cut severe diseaseStudy findings offer hope as omicron c
Two Doses of J&J’s Vaccine Slashes Omicron Hospital Stays
看
2.09K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3584582153384625","uuid":"3584582153384625","gmtCreate":1621488156539,"gmtModify":1625468765802,"name":"Investcub","pinyin":"investcub","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":38,"headSize":330,"tweetSize":252,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.08","exceedPercentage":"93.09%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9941981183,"gmtCreate":1679918336142,"gmtModify":1679918338542,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/OIG\">$Orbital Infrastructure Group, Inc.(OIG)$ </a>","listText":"<a href=\"https://ttm.financial/S/OIG\">$Orbital Infrastructure Group, Inc.(OIG)$ </a>","text":"$Orbital Infrastructure Group, Inc.(OIG)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9941981183","isVote":1,"tweetType":1,"viewCount":1797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9967472855,"gmtCreate":1670374244377,"gmtModify":1676538354483,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$ </a><v-v data-views=\"1\"></v-v>","listText":"<a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$ </a><v-v data-views=\"1\"></v-v>","text":"$Alibaba(BABA)$","images":[{"img":"https://community-static.tradeup.com/news/96ae343b1ea8f5da18f5e7fb375bb765","width":"750","height":"1249"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9967472855","isVote":1,"tweetType":1,"viewCount":1546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9026438335,"gmtCreate":1653414560027,"gmtModify":1676535277111,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/OEG\">$Orbital Energy Group(OEG)$</a>😔","listText":"<a href=\"https://ttm.financial/S/OEG\">$Orbital Energy Group(OEG)$</a>😔","text":"$Orbital Energy Group(OEG)$😔","images":[{"img":"https://community-static.tradeup.com/news/afbe1663b0bf5c59af6abefdf6551146","width":"828","height":"1632"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026438335","isVote":1,"tweetType":1,"viewCount":2282,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3580011914778910","authorId":"3580011914778910","name":"VivianChua","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"authorIdStr":"3580011914778910","idStr":"3580011914778910"},"content":"will recover 💚","text":"will recover 💚","html":"will recover 💚"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9026431530,"gmtCreate":1653414439120,"gmtModify":1676535277104,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a>To the sky pls...","listText":"<a href=\"https://ttm.financial/S/BABA\">$Alibaba(BABA)$</a>To the sky pls...","text":"$Alibaba(BABA)$To the sky pls...","images":[{"img":"https://community-static.tradeup.com/news/a9c85fb50b60fbdb692dbabcb7bf44a5","width":"750","height":"2627"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026431530","isVote":1,"tweetType":1,"viewCount":2057,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9030481474,"gmtCreate":1645785280000,"gmtModify":1676534064066,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"Bracing ... 🤕","listText":"Bracing ... 🤕","text":"Bracing ... 🤕","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030481474","repostId":"1185987372","repostType":4,"repost":{"id":"1185987372","kind":"news","pubTimestamp":1645783612,"share":"https://ttm.financial/m/news/1185987372?lang=&edition=fundamental","pubTime":"2022-02-25 18:06","market":"us","language":"en","title":"U.S. Stocks Poised to Fall as Russia Continues Ukraine Onslaught","url":"https://stock-news.laohu8.com/highlight/detail?id=1185987372","media":"The Wall Street Journal","summary":"Stock futures decline, while Russian shares jump and oil prices edge higherU.S. stocks were poised f","content":"<html><head></head><body><p>Stock futures decline, while Russian shares jump and oil prices edge higher</p><p><img src=\"https://static.tigerbbs.com/1e9ee2e50f421d60d5ee0a2e060e8607\" tg-width=\"1184\" tg-height=\"692\" width=\"100%\" height=\"auto\"/></p><p>U.S. stocks were poised for further volatility, as investors sought to make sense of the potentially far-reaching implications of war in Ukraine for individual companies and the wider economy.</p><p>Futures for the S&P 500 fell 1.2% Friday, a day after the benchmark index capped a wild trading session by closing 1.5% higher, as investors piled into growth and technology stocks. Futures for the Dow Jones Industrial Average fell 1% and those for the technology-focused Nasdaq-100 lost 1.4% Friday.</p><p>Overseas, markets regained some poise after sanctions laid out by President Bidenstopped short of some of the most severe measures investors had thought might be on the table. Russia’s Moex stock-market gauge, which endured a historic blow Thursday, rose 12.9%.</p><p>The Stoxx Europe 600 rose 0.7%, led by shares of resource and travel companies. Japan’s Nikkei 225 rose 2%, and the CSI 300, which comprises the largest stocks listed in Shanghai and Shenzhen, rose 1%, after both fell Thursday. Hong Kong’s Hang Seng Index slipped 0.6%.</p><p>In energy markets, futures for Brent crude, the global oil benchmark, rose 1.5% to $96.81 a barrel, while European natural-gas prices retreated by almost a quarter after rocketing Thursday.Brent topped $100 a barrel early Thursday before falling back.</p><p>Russian forces renewed bombing Ukraine early Friday, with central Kyiv rocked by explosions. Investors are pondering how the fighting, its effect on commodity markets and retaliatory Western sanctions will ripple through a world economy already grappling with elevated inflation and coming interest-rate rises by major central banks.</p><p>The U.S. and its allies have laid out stiff restrictions on Russian companies and their ability to interact with the international financial system. The European Union will formally sign off on sanctions Friday that willc ut 70% of Russia’s banking system off from international financial markets. Officials in Ukraine, the Baltics and the U.K. are calling for the sanctions to go further, cutting Russia off completely from infrastructure that ties together banks around the world.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b508620b24a78a56758f2e1dd2935e59\" tg-width=\"1050\" tg-height=\"699\" width=\"100%\" height=\"auto\"/><span>Investors are pondering how sanctions will affect the global economy.</span></p><p>“I do not think that this highly volatile period is already coming to an end,” said Daniel Egger, chief investment officer at St. Gotthard Fund Management. “Right now we have to focus now on what’s happening in Kyiv, how bloody the coming days will be, and I would say definitely the Russian sanctions still can be stepped up.”</p><p>In bond markets, yields fell in a sign investors still sought the safety of safe-haven assets. The yield on the benchmark U.S. 10-year Treasury note declined to 1.949% from 1.969% Thursday. Yields and prices move inversely. Gold prices, however, slipped 0.7% to $1,914 a troy ounce.</p><p>Among individual European stocks, some companies that were hammered at the start of Russia’s attack clawed back some lost ground. Russian gold producer Polymetal International rose 14%. Hungarian budget airline Wizz Air rose 4.9%. But banks with exposure to Russia or commodity markets came under pressure, including ING Groep,Société Générale and UniCredit. Shares of British arms and aerospace company BAE Systems, which has gained on the prospect of higher defense spending, added a further 4.3%.</p><p>“It looks like the military action in Ukraine could be protracted,” said Yung-Yu Ma, chief investment strategist for BMO Wealth Management in the U.S. In this case, short-term market movement is difficult to predict, he said.</p><p>Rapid inflation and the prospect of tighter monetary policy were complicating the outlook for some traditional safe-haven assets such as Treasury bonds, the U.S. dollar and gold, Mr. Ma added.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Stocks Poised to Fall as Russia Continues Ukraine Onslaught</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Stocks Poised to Fall as Russia Continues Ukraine Onslaught\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-25 18:06 GMT+8 <a href=https://www.wsj.com/articles/global-stocks-markets-dow-update-02-25-22-11645771218?page=1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stock futures decline, while Russian shares jump and oil prices edge higherU.S. stocks were poised for further volatility, as investors sought to make sense of the potentially far-reaching ...</p>\n\n<a href=\"https://www.wsj.com/articles/global-stocks-markets-dow-update-02-25-22-11645771218?page=1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.wsj.com/articles/global-stocks-markets-dow-update-02-25-22-11645771218?page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185987372","content_text":"Stock futures decline, while Russian shares jump and oil prices edge higherU.S. stocks were poised for further volatility, as investors sought to make sense of the potentially far-reaching implications of war in Ukraine for individual companies and the wider economy.Futures for the S&P 500 fell 1.2% Friday, a day after the benchmark index capped a wild trading session by closing 1.5% higher, as investors piled into growth and technology stocks. Futures for the Dow Jones Industrial Average fell 1% and those for the technology-focused Nasdaq-100 lost 1.4% Friday.Overseas, markets regained some poise after sanctions laid out by President Bidenstopped short of some of the most severe measures investors had thought might be on the table. Russia’s Moex stock-market gauge, which endured a historic blow Thursday, rose 12.9%.The Stoxx Europe 600 rose 0.7%, led by shares of resource and travel companies. Japan’s Nikkei 225 rose 2%, and the CSI 300, which comprises the largest stocks listed in Shanghai and Shenzhen, rose 1%, after both fell Thursday. Hong Kong’s Hang Seng Index slipped 0.6%.In energy markets, futures for Brent crude, the global oil benchmark, rose 1.5% to $96.81 a barrel, while European natural-gas prices retreated by almost a quarter after rocketing Thursday.Brent topped $100 a barrel early Thursday before falling back.Russian forces renewed bombing Ukraine early Friday, with central Kyiv rocked by explosions. Investors are pondering how the fighting, its effect on commodity markets and retaliatory Western sanctions will ripple through a world economy already grappling with elevated inflation and coming interest-rate rises by major central banks.The U.S. and its allies have laid out stiff restrictions on Russian companies and their ability to interact with the international financial system. The European Union will formally sign off on sanctions Friday that willc ut 70% of Russia’s banking system off from international financial markets. Officials in Ukraine, the Baltics and the U.K. are calling for the sanctions to go further, cutting Russia off completely from infrastructure that ties together banks around the world.Investors are pondering how sanctions will affect the global economy.“I do not think that this highly volatile period is already coming to an end,” said Daniel Egger, chief investment officer at St. Gotthard Fund Management. “Right now we have to focus now on what’s happening in Kyiv, how bloody the coming days will be, and I would say definitely the Russian sanctions still can be stepped up.”In bond markets, yields fell in a sign investors still sought the safety of safe-haven assets. The yield on the benchmark U.S. 10-year Treasury note declined to 1.949% from 1.969% Thursday. Yields and prices move inversely. Gold prices, however, slipped 0.7% to $1,914 a troy ounce.Among individual European stocks, some companies that were hammered at the start of Russia’s attack clawed back some lost ground. Russian gold producer Polymetal International rose 14%. Hungarian budget airline Wizz Air rose 4.9%. But banks with exposure to Russia or commodity markets came under pressure, including ING Groep,Société Générale and UniCredit. Shares of British arms and aerospace company BAE Systems, which has gained on the prospect of higher defense spending, added a further 4.3%.“It looks like the military action in Ukraine could be protracted,” said Yung-Yu Ma, chief investment strategist for BMO Wealth Management in the U.S. In this case, short-term market movement is difficult to predict, he said.Rapid inflation and the prospect of tighter monetary policy were complicating the outlook for some traditional safe-haven assets such as Treasury bonds, the U.S. dollar and gold, Mr. Ma added.","news_type":1,"symbols_score_info":{"ESmain":0.9,".DJI":0.9,"YMmain":0.9,"NQmain":0.9,".SPX":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":1698,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004297598,"gmtCreate":1642605034120,"gmtModify":1676533726958,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004297598","repostId":"2204307707","repostType":4,"repost":{"id":"2204307707","kind":"highlight","pubTimestamp":1642597998,"share":"https://ttm.financial/m/news/2204307707?lang=&edition=fundamental","pubTime":"2022-01-19 21:13","market":"us","language":"en","title":"3 Unstoppable Growth Stocks to Buy If There's a Stock Market Sell-Off","url":"https://stock-news.laohu8.com/highlight/detail?id=2204307707","media":"Motley Fool","summary":"These three top growth names are already down a lot and trade at fair prices, but could become really huge bargains if the market falls more amid rising interest rates.","content":"<div>\n<p>Amid fears over interest rate hikes, many top growth stocks are down 20%, 40%, or even 60% or more from their all-time highs in a relatively short amount of time. Higher inflation and interest rates ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/18/3-unstoppable-growth-stocks-to-buy-if-theres-a-sto/\">Web Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Growth Stocks to Buy If There's a Stock Market Sell-Off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Growth Stocks to Buy If There's a Stock Market Sell-Off\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-19 21:13 GMT+8 <a href=https://www.fool.com/investing/2022/01/18/3-unstoppable-growth-stocks-to-buy-if-theres-a-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amid fears over interest rate hikes, many top growth stocks are down 20%, 40%, or even 60% or more from their all-time highs in a relatively short amount of time. Higher inflation and interest rates ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/18/3-unstoppable-growth-stocks-to-buy-if-theres-a-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","SE":"Sea Ltd","BK4551":"寇图资本持仓","BK4566":"资本集团","STNE":"StoneCo","BK4528":"SaaS概念","BK4085":"互动家庭娱乐","CRWD":"CrowdStrike Holdings, Inc.","BK4554":"元宇宙及AR概念","BK4560":"网络安全概念","BK4548":"巴美列捷福持仓","BK4106":"数据处理与外包服务","BK4532":"文艺复兴科技持仓","BK4097":"系统软件","BK4535":"淡马锡持仓","BK4503":"景林资产持仓"},"source_url":"https://www.fool.com/investing/2022/01/18/3-unstoppable-growth-stocks-to-buy-if-theres-a-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204307707","content_text":"Amid fears over interest rate hikes, many top growth stocks are down 20%, 40%, or even 60% or more from their all-time highs in a relatively short amount of time. Higher inflation and interest rates could hurt the present value of future earnings, causing many high-multiple stocks to sell off.To be fair, after stratospheric runs through the pandemic, a lot of top growth names had gotten ahead of themselves, so the declines have seemed reasonable. However, some best-in-class growth stocks have now been thoroughly discounted. If the pain continues, these top names would become absolute bargains for the forward-thinking investor.Image source: Getty Images.1. Sea LimitedShares of Southeast Asian mobile gaming, e-commerce, and digital finance company Sea Limited (NYSE:SE) have been more than cut in half in just two months. Sure, the company reported slowing sequential growth in its profitable digital entertainment segment last quarter, which is heavily influenced by the four-year-old gaming hit Free Fire. However, it was somewhat inevitable that mobile-gaming growth might soften, as the third quarter marked the first summer since vaccines were widely available.Meanwhile, Sea's highest-growth businesses, including its Shopee e-commerce platform and SeaMoney digital finance ecosystem, showed strong growth. E-commerce revenue rocketed 134% last quarter, and SeaMoney surged more than 800%, albeit off a small base.Yes, Chinese internet giant Tencent did just sell some of its Sea Limited stake, which could shake others' confidence in the company. But Tencent really just sold off a small portion of its holdings, decreasing its economic interest in Sea from 21.3% to 18.7%. That's just a 12% trimming of its position. In addition, Tencent is converting super-voting shares to regular shares, so its voting power will go under 10%.The move might actually be due to the fact that Sea is rapidly expanding around the world, entering the huge markets of India and Europe last year. Likely, customers and authorities in those countries wouldn't want a company overly influenced by China to be too successful or retain too much consumer data. So the divestiture and reduction in Tencent's voting share could have been necessary for Sea to succeed in its next wave of growth.After Sea's rapid correction, its stock trades for just eight times revenue. And while the company is burning through cash, it still has about $7 billion in net cash on its balance sheet, and it grew revenue by more than 120% last quarter. It's hard to say when these types of stocks will bottom, but Sea is still executing quite well, and its growth path is long.2. CrowdStrikeAlthough it's already 40% off its highs, CrowdStrike Holdings (NASDAQ:CRWD) still trades at an expensive-looking 34 times sales, so it could very well sell off further.But it also might not. CrowdStrike is a best-in-class cloud security company that can justify its high valuation. Not only is its patented Falcon agent and Threat Graph architecture taking market share from legacy cyber players, but the overall cybersecurity market itself also should grow at double-digit rates for the next decade, especially in the cloud, where CrowdStrike excels.The company grew annualized recurring revenue by 67% last quarter, and added customers at an even higher 75% clip, with a net retention rate of 125%. But it isn't resting on those laurels, as it's still investing heavily, both internally and through acquisitions, to expand its offerings from endpoint security to an entire comprehensive cybersecurity platform.The company sees its total addressable market growing to $55 billion next year, up from $25 billion at its initial public offering, and growing to a potential $116 billion by 2025 as enterprises are forced to invest more in cloud-based security amid rising threats.What I like most about CrowdStrike is the network effect of its platform, which uses a combination of artificial intelligence and centralization that enables its Threat Graph to become smarter the more clients it gets. With that compounding advantage and huge growth opportunity, the stock is a definite buy target amid any further sell-off.3. StoneCoBrazilian payments company StoneCo (NASDAQ:STNE) is down nearly 80% over the past year and carries a market cap of just $5 billion today, so it might be hard to see how it falls further. But of course, anything is possible.StoneCo's stock has been decimated amid high inflation and surging interest rates in Brazil. While its payment processing business shouldn't be too affected, since it takes a fixed percentage of every transaction that goes through its merchant customers, other elements of its business have been negatively affected.Mainly, StoneCo had been ramping up its merchant lending in the third quarter just as interest rates have spiked, which could be a problem. Brazil's economic picture has deteriorated somewhat, which is not exactly the type of environment in which you want to make more loans. In addition, StoneCo has to borrow on its own lines of credit to fund the loans, but it has been reluctant to raise rates on customers as rapidly as its own interest costs have gone up. So margins in its credit business have come down.At the same time, StoneCo is also doubling down on certain growth initiatives. Management wants the company to branch out from its core high-margin payments processing business to become a comprehensive digital open-banking solution across enterprise resource planning, order management software, insurance, and other digital banking products.These growth initiatives could make StoneCo a much bigger business in the long run, but it's requiring investment now. So the company's high 30.8% adjusted net income margin in the third quarter of 2020 plummeted to just a 9% net profit margin last quarter, with adjusted net profits falling 53.9% over the prior year.While that drop looks scary, revenue did also surge 57.3% as management refocuses on growth over profits right now, coming out of the pandemic. If its initiatives work out, and if Brazil's economy doesn't deteriorate too much, margins should rise again and the stock could bounce back in a big way. So investors should definitely look to this high-risk, high-reward growth stock amid any further sell-off.","news_type":1,"symbols_score_info":{"CRWD":1,"STNE":1,"SE":1}},"isVote":1,"tweetType":1,"viewCount":1797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004657243,"gmtCreate":1642596304461,"gmtModify":1676533725780,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"Insightful !","listText":"Insightful !","text":"Insightful !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004657243","repostId":"2204081628","repostType":4,"repost":{"id":"2204081628","kind":"highlight","pubTimestamp":1642580000,"share":"https://ttm.financial/m/news/2204081628?lang=&edition=fundamental","pubTime":"2022-01-19 16:13","market":"us","language":"en","title":"Intel stock has a bright near-term future, says analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2204081628","media":"MarketWatch","summary":"Despite lingering long-term challenges, Intel could deliver a positive earnings surprise, analyst sa","content":"<html><head></head><body><p>Despite lingering long-term challenges, Intel could deliver a positive earnings surprise, analyst says</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/713259c13e9147c20cad50a5f5eed047\" tg-width=\"1050\" tg-height=\"699\" width=\"100%\" height=\"auto\"/><span>Intel shares could perform well ahead of the company’s February investor event, says an analyst.</span></p><p>Intel Corp. shares may have some bright spots ahead--at least in the very near future.</p><p>Citi Research analyst Christopher Danely likes the setup for the chipmaker's stock in the weeks to come, given the potential for a positive earnings surprise and optimism heading into the company's February investor day.</p><p>While Danely still has a neutral rating on Intel's shares, he added a "positive Catalyst Watch" designation to the name on Tuesday, which he said reflects expectations for near-term upside.</p><p>Danely thinks that demand for personal computers has been "well above expectations" given the "resurgent enterprise refresh." That trend could help Intel positively surprise with its fourth-quarter results and first-quarter outlook, he reasoned. The company is due to report results after the closing bell on Wednesday, Jan. 26.</p><p>Further, he anticipates that Intel's stock will "trade well ahead of its investor meeting, scheduled for Feb. 17.</p><p>Beyond that, he sees some longer-term challenges in store for Intel. For one, he argued that "considerable effort and focus still will be needed by Intel, especially in manufacturing, to catch up to its competitors." Danely also thinks that PC demand will "revert to the mean given two straight years of double digit growth."</p><p>Shares of Intel fell 1.7% on Tuesday. They've gained 1.3% over the past three months as the Dow Jones Industrial Average has risen 0.4%.</p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel stock has a bright near-term future, says analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel stock has a bright near-term future, says analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-19 16:13 GMT+8 <a href=https://www.marketwatch.com/story/intel-stock-has-a-bright-near-term-future-says-analyst-11642535769?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite lingering long-term challenges, Intel could deliver a positive earnings surprise, analyst saysIntel shares could perform well ahead of the company’s February investor event, says an analyst....</p>\n\n<a href=\"https://www.marketwatch.com/story/intel-stock-has-a-bright-near-term-future-says-analyst-11642535769?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓","BK4141":"半导体产品","BK4535":"淡马锡持仓","BK4554":"元宇宙及AR概念","BK4515":"5G概念","BK4527":"明星科技股","BK4512":"苹果概念","BK4529":"IDC概念"},"source_url":"https://www.marketwatch.com/story/intel-stock-has-a-bright-near-term-future-says-analyst-11642535769?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204081628","content_text":"Despite lingering long-term challenges, Intel could deliver a positive earnings surprise, analyst saysIntel shares could perform well ahead of the company’s February investor event, says an analyst.Intel Corp. shares may have some bright spots ahead--at least in the very near future.Citi Research analyst Christopher Danely likes the setup for the chipmaker's stock in the weeks to come, given the potential for a positive earnings surprise and optimism heading into the company's February investor day.While Danely still has a neutral rating on Intel's shares, he added a \"positive Catalyst Watch\" designation to the name on Tuesday, which he said reflects expectations for near-term upside.Danely thinks that demand for personal computers has been \"well above expectations\" given the \"resurgent enterprise refresh.\" That trend could help Intel positively surprise with its fourth-quarter results and first-quarter outlook, he reasoned. The company is due to report results after the closing bell on Wednesday, Jan. 26.Further, he anticipates that Intel's stock will \"trade well ahead of its investor meeting, scheduled for Feb. 17.Beyond that, he sees some longer-term challenges in store for Intel. For one, he argued that \"considerable effort and focus still will be needed by Intel, especially in manufacturing, to catch up to its competitors.\" Danely also thinks that PC demand will \"revert to the mean given two straight years of double digit growth.\"Shares of Intel fell 1.7% on Tuesday. They've gained 1.3% over the past three months as the Dow Jones Industrial Average has risen 0.4%.","news_type":1,"symbols_score_info":{"INTC":1}},"isVote":1,"tweetType":1,"viewCount":2405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006194130,"gmtCreate":1641628947957,"gmtModify":1676533636092,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"Great to learn about Vir Biotech….","listText":"Great to learn about Vir Biotech….","text":"Great to learn about Vir Biotech….","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006194130","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://ttm.financial/m/news/1134509683?lang=&edition=fundamental","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<html><head></head><body><p>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><b>A safe harbor in stormy weather</b></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p>What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p>But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p>So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><b>Revenue forecasts for Novavax: $2 billion to $8 billion</b></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.</p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.</p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><b>The antibody market all to itself</b></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.</p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p>And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-08 11:29 GMT+8 <a href=https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","VIR":"Vir Biotechnology, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax: $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"VIR":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008258351,"gmtCreate":1641467616308,"gmtModify":1676533618062,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"Another company added to watchlist!!!!","listText":"Another company added to watchlist!!!!","text":"Another company added to watchlist!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008258351","repostId":"1116653019","repostType":4,"repost":{"id":"1116653019","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641460234,"share":"https://ttm.financial/m/news/1116653019?lang=&edition=fundamental","pubTime":"2022-01-06 17:10","market":"us","language":"en","title":"Alterity Therapeutics Soared Over 36% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1116653019","media":"Tiger Newspress","summary":"Alterity Therapeutics soared over 36% in premarket trading.Alterity Therapeutics (ASX:ATH) secured a","content":"<html><head></head><body><p>Alterity Therapeutics soared over 36% in premarket trading.<img src=\"https://static.tigerbbs.com/4e761b186bdb71cae54640b4ab798107\" tg-width=\"768\" tg-height=\"560\" width=\"100%\" height=\"auto\"/>Alterity Therapeutics (ASX:ATH) secured a US patent for compounds to treat neurodegenerative diseases, including Parkinson's and Alzheimer's diseases.</p><p>The patent covers more than 80 compounds and secures exclusivity for a new class of iron chaperones, which would redistribute excess iron implicated in many neurodegenerative diseases, according to a Thursday news release.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alterity Therapeutics Soared Over 36% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlterity Therapeutics Soared Over 36% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-06 17:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Alterity Therapeutics soared over 36% in premarket trading.<img src=\"https://static.tigerbbs.com/4e761b186bdb71cae54640b4ab798107\" tg-width=\"768\" tg-height=\"560\" width=\"100%\" height=\"auto\"/>Alterity Therapeutics (ASX:ATH) secured a US patent for compounds to treat neurodegenerative diseases, including Parkinson's and Alzheimer's diseases.</p><p>The patent covers more than 80 compounds and secures exclusivity for a new class of iron chaperones, which would redistribute excess iron implicated in many neurodegenerative diseases, according to a Thursday news release.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATHE":"Alterity Therapeutics Limited"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116653019","content_text":"Alterity Therapeutics soared over 36% in premarket trading.Alterity Therapeutics (ASX:ATH) secured a US patent for compounds to treat neurodegenerative diseases, including Parkinson's and Alzheimer's diseases.The patent covers more than 80 compounds and secures exclusivity for a new class of iron chaperones, which would redistribute excess iron implicated in many neurodegenerative diseases, according to a Thursday news release.","news_type":1,"symbols_score_info":{"ATHE":0.9}},"isVote":1,"tweetType":1,"viewCount":2416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003950712,"gmtCreate":1640858492350,"gmtModify":1676533548443,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584582153384625","idStr":"3584582153384625"},"themes":[],"htmlText":"Good to know ","listText":"Good to know ","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003950712","repostId":"1180506204","repostType":4,"repost":{"id":"1180506204","kind":"news","pubTimestamp":1640852448,"share":"https://ttm.financial/m/news/1180506204?lang=&edition=fundamental","pubTime":"2021-12-30 16:20","market":"us","language":"en","title":"Two Doses of J&J’s Vaccine Slashes Omicron Hospital Stays","url":"https://stock-news.laohu8.com/highlight/detail?id=1180506204","media":"Bloomberg","summary":"Booster shot following the one-dose vaccine cut severe diseaseStudy findings offer hope as omicron c","content":"<div>\n<p>Booster shot following the one-dose vaccine cut severe diseaseStudy findings offer hope as omicron cases soar worldwideA health worker prepares doses of the Johnson & Johnson Covid-19 vaccine in Cape ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-30/two-doses-of-j-j-s-vaccine-slashed-omicron-hospital-stays\">Web Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Two Doses of J&J’s Vaccine Slashes Omicron Hospital Stays</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwo Doses of J&J’s Vaccine Slashes Omicron Hospital Stays\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 16:20 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-12-30/two-doses-of-j-j-s-vaccine-slashed-omicron-hospital-stays><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Booster shot following the one-dose vaccine cut severe diseaseStudy findings offer hope as omicron cases soar worldwideA health worker prepares doses of the Johnson & Johnson Covid-19 vaccine in Cape ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-30/two-doses-of-j-j-s-vaccine-slashed-omicron-hospital-stays\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-30/two-doses-of-j-j-s-vaccine-slashed-omicron-hospital-stays","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180506204","content_text":"Booster shot following the one-dose vaccine cut severe diseaseStudy findings offer hope as omicron cases soar worldwideA health worker prepares doses of the Johnson & Johnson Covid-19 vaccine in Cape Town, South Africa. Photographer: Dwayne Senior/BloombergTwo doses of Johnson & Johnson’s Covid-19 vaccine slashed hospitalizations caused by the omicron variant in South Africa by up to 85%, a critical finding since the shot is being increasingly relied upon across the continent, researchers said.The results are a welcome bit of news as the explosive rise of omicron pushes the world to a record number of daily cases, and evidence emerges that the highly mutated strain can evade the protection that normally stems from vaccination. They also could help explain why hospitalizations and deaths aren’t following the exponential growth in new cases.Visitors queue for vaccines at the Discovery Ltd. mass Covid-19 vaccination site in Johannesburg, South Africa, on Thursday, Dec. 9, 2021.Photographer: Waldo Swiegers/BloombergThe study from the South African Medical Research Council found that protection levels rose in the weeks and months after a booster dose was given to those who previously received the J&J vaccine. It prevented 85% of hospitalizations one to two months after the second shot was given, up from 63% for people who received the booster within the past two weeks.“The results are important and reassuring,” said Glenda Gray, the lead researcher and president of the South African Medical Research Council. The study, one of the largest of its kind in the world, “shows at a global level that this regimen can be useful,” Gray said in a telephone interview.Almost half a million South African health workers were given J&J vaccines as part of a major trial ahead of the country’s general rollout earlier this year. They were offered boosters of the same single-shot dose starting in November, paving the way for this research.Dominant StrainThe researchers tracked hospitalizations that occurred from Nov. 8 through Dec. 17 in South Africa, when omicron quickly became the dominant strain circulating in the nation. They compared the records of 69,092 health care workers who got the J&J vaccine to a matched group of unvaccinated individuals who were enrolled in the same managed care organization.There were 713 hospital admissions among those who were unvaccinated, compared to 10 for those who got the booster within two weeks, 8 for those who got it two weeks to a month earlier, and three among those who got it more than a month prior.The results are the first evidence that a second dose of the J&J shot given six to nine months after an initial injection is effective against severe infection caused by omicron, the investigators said in the study, posted on medRxiv.org.Johnson & Johnson shipped globally more than 200 million doses of its vaccine as of mid-December, making it the seventh-biggest shot in the world, according to health analytics company Airfinity.The study was funded by the government as well as donors including the Solidarity Response Fund NPC, The Michael & Susan Dell Foundation, The Elma Vaccines and Immunization Foundation and the Bill & Melinda Gates Foundation.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":2086,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}